UBS Group AG — Director's Dealing 2024

Sep 5, 2024

SEC Form 4/A — Form 4/A

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2024-08-27

Reporting Person: UBS Group AG (Market maker/broker-dealer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-27	Common Stock	P	0	—	Acquired	146012	Indirect

Footnotes

F1: This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group.

F2: This Form 4 Amendment is being filed to correct and replace the original Form 4 filed on August 29, 2024. Subsequent to the date of first filing, the Reporting Person confirmed directly with the Issuer that, due to certain warrant exercises effected on August 27, 2024, the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024 was 16,932,593 shares. When taking the revised share count into consideration, the Reporting Person determined it never beneficially owned more than 10% of ENDRA shares. Therefore the Form 4 previously filed by the Reporting Person was erroneous and unnecessary